[go: up one dir, main page]

GT201600190A - Compuestos químicos - Google Patents

Compuestos químicos

Info

Publication number
GT201600190A
GT201600190A GT201600190A GT201600190A GT201600190A GT 201600190 A GT201600190 A GT 201600190A GT 201600190 A GT201600190 A GT 201600190A GT 201600190 A GT201600190 A GT 201600190A GT 201600190 A GT201600190 A GT 201600190A
Authority
GT
Guatemala
Prior art keywords
derivatives
chemical compounds
compounds
enac
cpd
Prior art date
Application number
GT201600190A
Other languages
English (en)
Inventor
Susanne Elisabeth Berglund
Stephen Connolly
Martin Hemmerling
Nafizal Hossain
Anna Kristoffersson
Johan Rune Michael Lundkvist
Grigorios Nikitidis
Lena Elisabeth Ripa
Igor Shamovsky
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of GT201600190A publication Critical patent/GT201600190A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS DE PIRAZINA CON ACTIVIDAD FARMACÉUTICA, A PROCESOS PARA LA PREPARAR TALES DERIVADOS, A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TALES DERIVADOS Y AL USO DE TALES COMPUESTOS EN EL TRATAMIENTO DE UN ESTADO DE ENFERMEDAD MEDIADO POR ENAC (TAL COMO ASMA, CF O CPD).
GT201600190A 2014-03-18 2016-09-14 Compuestos químicos GT201600190A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461954674P 2014-03-18 2014-03-18

Publications (1)

Publication Number Publication Date
GT201600190A true GT201600190A (es) 2019-07-29

Family

ID=52780553

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201600190A GT201600190A (es) 2014-03-18 2016-09-14 Compuestos químicos

Country Status (39)

Country Link
US (3) US9873678B2 (es)
EP (1) EP3119752B1 (es)
JP (1) JP6502469B2 (es)
KR (1) KR102296041B1 (es)
CN (1) CN106103423B (es)
AP (1) AP2016009447A0 (es)
AR (1) AR099790A1 (es)
AU (1) AU2015233195B2 (es)
CA (1) CA2941807C (es)
CL (1) CL2016002303A1 (es)
CR (1) CR20160479A (es)
CY (1) CY1120509T1 (es)
DK (1) DK3119752T3 (es)
DO (1) DOP2016000232A (es)
EA (1) EA029952B1 (es)
ES (1) ES2679618T3 (es)
GT (1) GT201600190A (es)
HR (1) HRP20181123T1 (es)
HU (1) HUE039425T2 (es)
IL (1) IL247610B (es)
LT (1) LT3119752T (es)
ME (1) ME03056B (es)
MX (1) MX368577B (es)
NI (1) NI201600134A (es)
NZ (1) NZ724063A (es)
PE (1) PE20170205A1 (es)
PH (1) PH12016501808B1 (es)
PL (1) PL3119752T3 (es)
PT (1) PT3119752T (es)
RS (1) RS57487B1 (es)
SG (1) SG11201607751SA (es)
SI (1) SI3119752T1 (es)
SM (1) SMT201800378T1 (es)
SV (1) SV2016005278A (es)
TR (1) TR201810207T4 (es)
TW (1) TWI687410B (es)
UY (1) UY36034A (es)
WO (1) WO2015140527A1 (es)
ZA (1) ZA201607136B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7608847B2 (ja) * 2021-01-27 2025-01-07 三菱瓦斯化学株式会社 エポキシ樹脂硬化剤、エポキシ樹脂組成物、及び塗料
GB202406247D0 (en) 2024-05-03 2024-06-19 Enterprise Therapeutics Ltd Compounds and pharmaceutical compositions

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577418A (en) 1969-02-12 1971-05-04 Merck & Co Inc Pyrazinamide derivatives and processes for their preparation
US3573306A (en) 1969-03-05 1971-03-30 Merck & Co Inc Process for preparation of n-substituted 3,5-diamino-6-halopyrazinamides
FI820266L (fi) 1981-02-02 1982-08-03 Ici Plc Alkanolaminderivater
DE3361244D1 (de) 1982-01-29 1986-01-02 Ici Plc Alkanolamine derivatives
GB8810933D0 (en) 1987-05-26 1988-06-15 Ici America Inc Heterocyclic compounds
GB8810934D0 (en) 1987-05-26 1988-06-15 Ici America Inc Amides
US4803206A (en) 1988-03-07 1989-02-07 Schering Corporation Antihypertensive acylpyrazines
GB8812343D0 (en) 1988-05-25 1988-06-29 Ici America Inc Amino compounds
GB8812342D0 (en) 1988-05-25 1988-06-29 Ici America Inc Bicyclic compounds
DK0966443T3 (da) 1997-02-26 2009-03-09 Pfizer Heteroaryl-hexansyre amidderivater, deres fremstilling og deres anvendelse som selektive inhibitorer af MIP-1-alfa binding til dens CCR1 receptor
GB9930557D0 (en) 1999-12-23 2000-02-16 Rolic Ag Optically active materials
AU5969101A (en) 2000-05-12 2001-11-26 Genzyme Corp Modulators of tnf-alpha signaling
EP1453789A2 (en) 2001-11-08 2004-09-08 Elan Pharmaceuticals, Inc. N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040087571A1 (en) 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
CA2510815A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
JP2008515978A (ja) 2004-10-13 2008-05-15 ユニバーシティ オブ コネチカット カンナビネルジック脂質リガンド
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
AU2008221263B2 (en) 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
DE602008005140D1 (de) 2007-05-07 2011-04-07 Novartis Ag Organische verbindungen
CA2707857C (en) 2007-12-10 2016-09-13 Novartis Ag Spirocyclic amiloride analogues
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP2011520831A (ja) 2008-05-13 2011-07-21 ノバルティス アーゲー ３，５−ジアミノ−６−クロロ−ピラジン−２−カルボン酸誘導体および気道疾患処置用上皮性ナトリウムチャネルブロッカーとしてのその使用
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
ES2535736T3 (es) * 2008-06-10 2015-05-14 Novartis Ag Derivados de pirazina como bloqueadores de los canales de sodio epitelial
WO2011028740A1 (en) * 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013192517A2 (en) 2012-06-21 2013-12-27 Whitehead Institute For Biomedical Research Compounds for treating infectious diseases
RU2015129065A (ru) 2012-12-17 2017-01-25 Пэрион Сайенсиз, Инк. Производные хлор-пиразинкарбоксамида, обладающие активностью блокирования эпителиальных натриевых каналов
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
EP2931712B8 (en) 2012-12-17 2018-05-23 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds

Also Published As

Publication number Publication date
PT3119752T (pt) 2018-07-24
PH12016501808A1 (en) 2017-01-09
DK3119752T3 (en) 2018-07-30
LT3119752T (lt) 2018-08-10
JP6502469B2 (ja) 2019-04-17
CA2941807C (en) 2023-03-07
CY1120509T1 (el) 2019-07-10
SMT201800378T1 (it) 2018-09-13
MX2016011681A (es) 2016-10-28
MX368577B (es) 2019-10-08
JP2017512830A (ja) 2017-05-25
SV2016005278A (es) 2016-11-30
UY36034A (es) 2015-09-30
KR102296041B1 (ko) 2021-08-30
CR20160479A (es) 2017-02-24
EA201691641A1 (ru) 2017-02-28
US9873678B2 (en) 2018-01-23
US20170107195A1 (en) 2017-04-20
SI3119752T1 (en) 2018-08-31
US10954211B2 (en) 2021-03-23
EP3119752B1 (en) 2018-05-16
US10336725B2 (en) 2019-07-02
ME03056B (me) 2018-10-20
AU2015233195B2 (en) 2017-04-20
NZ724063A (en) 2018-02-23
KR20160127135A (ko) 2016-11-02
RS57487B1 (sr) 2018-10-31
US20190330187A1 (en) 2019-10-31
CL2016002303A1 (es) 2017-01-13
ZA201607136B (en) 2018-04-25
AP2016009447A0 (en) 2016-09-30
CA2941807A1 (en) 2015-09-24
ES2679618T3 (es) 2018-08-29
IL247610A0 (en) 2016-11-30
TWI687410B (zh) 2020-03-11
EP3119752A1 (en) 2017-01-25
CN106103423A (zh) 2016-11-09
HRP20181123T1 (hr) 2018-09-21
AR099790A1 (es) 2016-08-17
PL3119752T3 (pl) 2018-09-28
PE20170205A1 (es) 2017-04-06
CN106103423B (zh) 2019-12-06
US20180162838A1 (en) 2018-06-14
AU2015233195A1 (en) 2016-09-22
PH12016501808B1 (en) 2017-01-09
TW201620880A (zh) 2016-06-16
DOP2016000232A (es) 2016-10-16
HUE039425T2 (hu) 2018-12-28
TR201810207T4 (tr) 2018-08-27
SG11201607751SA (en) 2016-10-28
WO2015140527A1 (en) 2015-09-24
IL247610B (en) 2019-05-30
NI201600134A (es) 2017-03-13
EA029952B1 (ru) 2018-06-29

Similar Documents

Publication Publication Date Title
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CO2017011851A2 (es) Compuestos novedosos
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CR20150326A (es) Inhibidores de autotaxina
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CL2014002257A1 (es) Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
CL2015001724A1 (es) Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros.
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CO2017002472A2 (es) Formulación de acetato de abiraterona
DOP2016000253A (es) Nuevos compuestos
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas